CINCINNATI, OH, USA (January 4, 2018) – Callitas Health Inc. (CSE: LILY, OTCBB: MPHMF, FWB: T3F2), (the “Company” or “Callitas”) a clinical-stage company developing innovative technologies for weight management and female health and wellness, today announced that Dr. Laura Berman has joined the Callitas team. She will fill the role of Chief Health Advisor, promoting ToConceive and providing insight and consultation on the development of the Company’s other products, both OTC and the prescription drug under development for female sexual dysfunction, Extrinsa.

Dr. Berman is a world-renowned sex and relationship educator, researcher and therapist, as well as TV, radio and internet host, presenting the weeknight radio program “Uncovered with Dr. Laura Berman.” She’s a New York Times best-selling author on sexual health and pleasure. Dr. Berman also acts as assistant clinical professor of OBGYN and psychiatry at the Feinberg School of Medicine at Northwestern University in Chicago.

The addition of Dr. Berman to the Callitas team emphasizes the Company’s commitment to female health and wellness and the importance of ToConceive, Extrinsa, and future sexual health and wellness products to the women’s health sphere. “Dr. Berman is one of the most recognized and respected experts and a pioneer in women’s sexual health,” said Kim Whittemore, women’s health advocate and Callitas board member. “She brings unparalleled reach and credibility to the Callitas products.”

About Callitas Health

Formed in early 2015, Callitas Health Inc. is a clinical-stage company developing innovative technologies for obesity, weight management and female health & wellness. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J’s LLC, the Company successfully launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive. www.toconceive.com.

Callitas Health Inc. trades on the Canadian Securities Exchange (CSE) under the ticker symbol “LILY” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval and the commercialization of the rights to the Company’s biomedical & drug technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: CannaMint Strips, C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

ABOUT CALLITAS

As a company, our number one goal is helping people by bringing products to market that improve quality of life. All our drug treatments and biomedical technologies fit our mission to deliver breakthrough products and services that reduce invasiveness and enhance daily living.